AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05427903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine
Description: Buccal infiltration after IANB
Study NCT05427903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine
Description: Buccal infiltration after IANB
Study NCT04990492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paper GAD 7
Description: The paper based GAD 7 that is commonly accepted at clinics
Study NCT04990492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Voice Administered GAD 7
Description: This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
Study NCT04370457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of the MyPal ePRO system
Description: Patients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up
Study NCT06247644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device wear on skin
Description: Participant will wear the device over a period of 28 hours to assess adhesive performance and potential skin effects.
Study NCT05128734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.
Study NCT05128734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally twice daily in treatment arm 2.
Study NCT05048537 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 18F-FACBC PET/CT
Description: 10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
Study NCT04757350 — intervention group
Intervention type: OTHER
Intervention: Observational research, not applicable
Description: Observational research, not applicable
Study NCT05082129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransiCap
Description: The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
Study NCT04098354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: home BP telemonitoring system .
Description: Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
Study NCT04098354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: home BP telemonitoring system .
Description: Patients will receive a Bluetooth-enabled and validated electronic upper arm oscillometric BP device (A\&D Ltd. UA-651BLE; San Jose, CA) that will be paired to their smartphone. Patients will be required to sit with their back rested for at least 5 minutes with the BP cuff around their arm. They will then be required to push the start button on the HBPT device to initiate BP measurement. HBPT values will be based on a series comprised of the mean of duplicate measures, for morning and evening, for a 7-day period and the first day home BP values will not be considered. The BP data will be auto transmitted via Bluetooth to their smartphone and relayed to a secure web portal for review.
Study NCT06268769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Pill
Description: Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Study NCT06268769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus capsule
Description: Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Study NCT05686382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Wound Infusion
Description: continuous local anesthetic infiltration of the wound
Study NCT05686382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: ultrasound guided injection of local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles
Study NCT04008602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quick icing
Description: Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
Study NCT04008602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Cold
Description: Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the decreased nerve conduction velocity.
Study NCT04792957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: immunohistochemical methods
Description: The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
Study NCT05631977 — intervention group
Intervention type: OTHER
Intervention: Point of care ultrasound cardiac examination
Description: The study intervention consists of a POCUS cardiac examination by site approved personal using an FDA cleared US scanner. Usual care of study participants will not be impacted.
Study NCT06060093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Water, 5% collagen(w/w), octoacetate (1 mM)
Study NCT06060093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water, 5% collagen(w/w), octoacetate (1 mM)
Study NCT06060093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A total of 75g ketone ester supplementation will be administered in 3 bouts of 25g in order to establish intermittent exogenous ketosis: twice immediately after training, and one 30 minutes before sleep. The ketone ester used is (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Study NCT04620226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement
Description: Rapid Point-of-Care testing will provide participants with a HCV antibody and RNA result within 2 hours. If the participant is HCV RNA+, they will receive an inpatient consultation from a liver specialist prior to discharge. We hypothesize that this model will minimize losses in the continuum-of-care and improve linkages to care.
Study NCT05419063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss strategies
Description: Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress.
Study NCT05419063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-based and email feedback
Description: Participants will receive weekly text-based feedback based on dietary strategy tracking and weight tracking. Participants will receive tailored email support and synchronous problem solving sessions as needed.
Study NCT04488497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis
Description: This intervention will help people with RA get tested for hyperlipidemia so that they can later discuss with their physician how to better treat their increased risk for cardiovascular disease.
Study NCT04488497 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Participants in this group will not receive peer coaches calls. They will receive additional educational materials about CVD risk and the regular care provided by their doctors.
Study NCT04673565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Each participant in the treatment group will attend a 1-hour MI group session with 9 other participants hosted by a practicing MI therapies via Zoom at one month after the initial visit. This session will utilize MI to elicit motivation in each participant. Participants will also receive standard care delivered at in-person audiology clinic visits.
Study NCT04523766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness of Breath
Description: The Mindful Breathing intervention will be adapted from a validated, brief mindfulness training model. Participants will be instructed to focus on the sensations of the breath (i.e., at the tip of the nose and in the nostrils, abdomen and back) and, if a pain arises in the body, acknowledge it without judgement and return attention to the breath.
Study NCT04523766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Interoceptive Mapping
Description: The MIM intervention will be adapted from the core MORE meditation practice. Participants will be instructed to (1) zoom in to deconstruct pain into its constituent affectively-valenced physical sensations and precisely map each sensation's spatial location, (2) zoom out to broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that are absent of sensation and pleasant sensations), and (3) savor any pleasant sensations or experiences occurring during the mindfulness practice.
Study NCT05441917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sanae method with LED
Description: Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and phototherapy.
Study NCT05441917 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sanae method with Radiofrecuency
Description: Sanae method (combination of therapies): Manual therapy, Carboxytherapy, and radiofrequency.
Study NCT04886453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced general anesthesia without morphine
Description: Balanced general anesthesia without morphine
Study NCT04886453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard general anesthesia balanced with morphine
Description: Standard general anesthesia balanced with morphine
Study NCT04886453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection
Description: Data collection
Study NCT04886453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Data collection
Study NCT04886453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of pain
Description: visual analog scale
Study NCT04886453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of pain
Description: visual analog scale
Study NCT04886453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recovery quality score
Description: QoR15 questionnaire
Study NCT04886453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovery quality score
Description: QoR15 questionnaire
Study NCT05805098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
Study NCT05805098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
Study NCT05805098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
Study NCT04742647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double cerclage
Description: Two cervical cerlages will be placed
Study NCT04742647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single cerclage
Description: One cerclage will be placed
Study NCT05493085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Ultrasound-guided quadratus lumborum block
Study NCT05493085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural injection
Description: Single Caudal epidural injection
Study NCT04727086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.3656
Description: BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
Study NCT04727086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once daily in tablet form.
Study NCT04778774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Two different nerve block types, Adductor canal block group and Femoral nerve block group
Study NCT05419843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSCT Arm group
Description: Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT.
Study NCT05110274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Overnight Metabolic Flexibility
Description: Participants will spend 13 hours (overnight) in a metabolic chamber where they will be fed a single high-fat supper meal. Energy expenditure, respiratory exchange ratio (RER), and 12-h oxidation of CHO, fat, and protein will be calculated and used to determine metabolic flexibility, i.e. change in RER from baseline.
Study NCT05110274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clamp Metabolic Flexibility
Description: Metabolic flexibility with be assessed during a 2-step hyperinsulinemic-euglycemic clamp procedure. The clamp will be performed for four hours, two hours at an insulin dose of 10 mU/m\^2/min and two hours at an insulin dose of 80 mU/m\^2/min. Resting metabolic rate will be determined via hood indirect calorimetry at baseline, before insulin onset, and during the final 30 min of each step of the clamp. Metabolic flexibility will be determined by comparing the resting metabolic rate during baseline and during the final 30 min of each step of the clamp.
Study NCT06503562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: central nervous system focused treatment program
Description: Pain neuroscience education, breathing exercises and relaxation exercises with guided imagery
Study NCT06503562 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classical Physiotherapy
Description: All participants will receive conventional physiotherapy five days a week for one month. Transcutaneous electrical nerve stimulation, 15 min hotpack will be applied to the neck and back. Afterwards, mobilisations to the cervical and thoracic spine joints and myofascial release to the upper trapezius muscle will be applied. The patient will be given 3X10 neck active range of motion exercises to do at home every day and self stretches to the muscles in the neck region (SCM, upper trapezius, scalene and pectoral) according to the patient's condition. After the first week, strengthening exercises with isometric and resistive isotonic exercises will be given to the neck and upper back muscles gradually increasing. Patients will not be given any medication and will be asked not to use any medication.
Study NCT06503562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Physiotherapy
Description: All participants will receive conventional physiotherapy five days a week for one month. Transcutaneous electrical nerve stimulation, 15 min hotpack will be applied to the neck and back. Afterwards, mobilisations to the cervical and thoracic spine joints and myofascial release to the upper trapezius muscle will be applied. The patient will be given 3X10 neck active range of motion exercises to do at home every day and self stretches to the muscles in the neck region (SCM, upper trapezius, scalene and pectoral) according to the patient's condition. After the first week, strengthening exercises with isometric and resistive isotonic exercises will be given to the neck and upper back muscles gradually increasing. Patients will not be given any medication and will be asked not to use any medication.
Study NCT05893277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)
Description: Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
Study NCT06383520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-aGPC3-scFv/Fab
Description: For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis.
Study NCT04748796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography
Description: Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.
Study NCT04748796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Landiolol
Description: Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
Study NCT05224336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25mg oral psilocybin
Study NCT05224336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Niacin
Description: 100mg oral niacin
Study NCT04483076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA > 1.5 m2. Day 15 to day 21 is the rest period.
Study NCT04483076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA > 1.5 m2. Day 15 to day 21 is the rest period.
Study NCT04483076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.